Investors Research Corp Trims Position in Invesco S&P MidCap 400 Revenue ETF $RWK

Investors Research Corp lessened its holdings in shares of Invesco S&P MidCap 400 Revenue ETF (NYSEARCA:RWK) by 83.7% in the second quarter, Holdings Channel.com reports. The fund owned 4,099 shares of the company’s stock after selling 21,055 shares during the period. Investors Research Corp’s holdings in Invesco S&P MidCap 400 Revenue ETF were worth $599,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RWK. Farther Finance Advisors LLC purchased a new position in Invesco S&P MidCap 400 Revenue ETF during the 4th quarter valued at $30,000. Greenline Wealth Management LLC bought a new position in Invesco S&P MidCap 400 Revenue ETF in the fourth quarter worth about $67,000. Arax Advisory Partners bought a new position in Invesco S&P MidCap 400 Revenue ETF in the fourth quarter worth about $108,000. Sunbelt Securities Inc. bought a new position in Invesco S&P MidCap 400 Revenue ETF in the third quarter worth about $109,000. Finally, Trust Co. of Vermont purchased a new stake in Invesco S&P MidCap 400 Revenue ETF in the second quarter worth about $135,000.

Invesco S&P MidCap 400 Revenue ETF Stock Performance

Invesco S&P MidCap 400 Revenue ETF stock opened at $147.77 on Thursday. The stock’s 50 day simple moving average is $148.31 and its two-hundred day simple moving average is $140.45. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of 14.05 and a beta of 1.06. Invesco S&P MidCap 400 Revenue ETF has a fifty-two week low of $118.54 and a fifty-two week high of $152.74.

About Invesco S&P MidCap 400 Revenue ETF

RevenueShares Mid Cap ETF (the Fund) seeks to achieve its investment objective of outperforming the total return performance of the S&P MidCap 400 Index (S&P 400) by investing in the constituent securities of the S&P 400 in the same proportions as the RevenueShares Mid Cap Index. The Fund consists of the same constituent securities as the S&P 400. But rather than being weighted by market capitalization, the Fund employs a patent-pending investment methodology to weight stocks by annual revenue. The Fund is rebalanced annually.